Skip to main content
OpenTrials
Completed

NCT Number: NCT00962819

Measles, Mumps, and Rubella (MMR) Immunity in College Students

This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Measles Infections Mononegavirales Infections Morbillivirus Infections Mouth Diseases Mumps Paramyxoviridae Infections Parotid Diseases Parotitis RNA Virus Infections Rubella Rubivirus Infections Rubulavirus Infections Salivary Gland Diseases Stomatognathic Diseases Togaviridae Infections Virus Diseases

Age range

18 year–24 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Hope Clinic of the Emory Vaccine Center

Decatur, Georgia, 30030, United States

About this study

No additional description needed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability and willing to provide an informed consent
  • Documented receipt of MMR-II vaccination in childhood
  • Not pregnant

Exclusion criteria

  • No history of HIV infection.
  • Immunocompromised health status due to HIV infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy.
  • Use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications)
  • Medical conditions that require the use of immunosuppressive medications
  • Received blood or blood products within the last 30 days
  • Any vaccines received in the last 30 days

Treatment and study plan

MMR Vaccine

Biological

People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)

Other names: No other names

Primary outcomes

  1. Levels of mumps antibody and levels of memory B and T cell responses

    Time frame: Day 1 for all participants except for those who receive MMR vaccine, there will be additional outcome measures on Day 0, 7, 14 and 28 post-vaccination.

    Cross sectional measurement of antibodies to mumps. measles or rubella

Secondary outcomes

  1. Determine proportion of college-aged students who are seronegative for mumps

    Time frame: outcome measurement on Day 1

    Cross-sectional measurement of antibodies to mumps, measles and rubella

Sponsors and collaborators

Lead sponsor

Sri Edupuganti, MD MPH

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Aug 20, 2009
Registry last updated
Oct 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.